Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2021, with a specific transaction date of October 7, 2021. The report serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a disclosure of an insider transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of notional ADSs |
| Instrument | American Depositary Shares (ADSs) |
| Price per ADS | $38.66 |
| Volume | 1,293.531 ADSs |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It documents a single acquisition event within an executive savings plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transaction was executed within Dr. H. Barron's GSK Executive Supplemental Savings Plan account.
Key Facts for Investor Verification
- Insider Identity: Dr. H. Barron, Chief Scientific Officer and President, R&D.
- Transaction Nature: Acquisition of notional ADSs, not a direct open-market purchase of physical shares.
- Transaction Date: October 7, 2021.
- Financial Impact: The filing does not disclose the total monetary value of the transaction, only the unit price and volume.